Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...

Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...

The solution leverages AI to match molecular, demographic, and clinical history data against eligibility criteria from active trials. Credit: MUNGKHOOD STUDIO / Shutterstock.com. Anova Enterprises has ...

Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...

The trial is evaluating sabirnetug for early Alzheimer’s disease. Credit: Dragana Gordic / Shutterstock.com. Acumen Pharmaceuticals has dosed the first subject in the open-label extension (OLE) ...

The study included subjects aged between four and ten years for the treatment of Rett syndrome. Credit: Yuriy K / Shutterstock.com. Neurogene has announced encouraging interim clinical data in the ...

Roche’s oral BTK inhibitor, fenebrutinib, has demonstrated its efficacy in two different subsets of multiple sclerosis (MS) during two late-stage trials. Image credit: illustrissima via ...

The trial enrolled 73 subjects who had not responded satisfactorily to a minimum of one antidepressant during their current episode. Credit: daniiD / Shutterstock.com. Neurocrine Biosciences has ...

Amid geopolitical instability, professionals in the clinical trials segment must look to mitigate risks early through operational flexibility. Image credit: Athanasios Psimadis / Arena International.

If approved in AFRS, it would become the ninth US approved indication for Dupixent. Image credit: Angelina Avei / Shutterstock.com Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ...